Insights provides context and perspective about key pharmacy trends and issues

View article
Drug Pipeline
Updates on the robust gene therapy pipeline from CVS Health pipeline team to help payors stay abreast of this very important emerging category. More
Briefing
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's aducanumab will... More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q2-Q3 2020 More
Specialty Report
Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q1-Q2 2020 More
Specialty Report
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval timeframes More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q4 2019-Q1 2020 More
Specialty Report
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization strategies can... More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3-Q4 2019 More
Specialty Report
Drug Pipeline
Biosimilars are a critical tool PBMs can use to help increase market competition and lower costs – we made changes to our template formularies for categories that now have biosimilars... More
Feature